Anti-Tuberculosis Drugs against the Resistance Level of Mycobacterium tuberculosis isolates

Yusup Subagio Sutanto(1), Magdalena Sutanto Sutanto(2), Agnes Sri Harti(3),

DOI: https://doi.org/10.15294/kemas.v17i1.24158


(1) Program Studi Ilmu Penyakit Paru, Fakultas Kedokteran Universitas Negeri Sebelas Maret Surakarta
(2) RSUD Kota Surakarta
(3) Universitas Kusuma Husada Surakarta

Abstract

Prolonged MDR-TB therapy can have side effects, namely a correlation between cure rates and changes in bacterial profiles related to resistance to anti-tuberculosis drugs (ATD) which can affect the incidence rate of MTB and MDR-TB in a region. The research objective was to analyze the effectiveness of the type of ATD against the resistance level of Mycobacterium tuberculosis (MTB) isolates with the incidence of tuberculosis (TB) and MDR-TB. The research method used was a retrospective cohort based on tracing medical record data at the Surakarta City Center General Hospital 2016 until 2017 with total sampling. The independent variable of this study was the type of ATD, while the dependent variable was the resistance level of MTB isolates. The characteristics of the most patient respondent suspect TB were male with the level of resistance of MTB isolates to ATD relatively varied. The results of the analysis of different tests showed a p value of 0.000 so that the p value was <0.05, so there was an effect of the type of ATD (Strepttomycin, Isoniazid, Rifampicin and Ethambutol) on the resistance of TB isolates from patients with suspected TB. This is useful to determine the success of TB therapy in terms of mortality and the effectiveness of therapy in TB patients.

Keywords

ATD; M. tuberculosis; Isolate; Resistance; MTB; MDR-TB

Full Text:

PDF

References

Adane, K., Ameni, G., Bekele, S., Abebe, M., & Aseffa, A., 2015. Prevalence and Drug Resistance Profile of Mycobacterium tuberculosis Isolated from Pulmonary Tuberculosis Patients Attending Two Public Hospitals in East Gojjam Zone, Northwest Ethiopia. BMC Public Health, 15, pp.572.

Alene, K.A., Yi, H., Viney, K., McBryde, E.S., Yang, K., Bai, L., Gray, D.J., Clements, A.C.A., & Xu, Z., 2017. Treatment Outcomes of Patients With Multidrug-resistant and Extensively Drug Resistant Tuberculosis in Hunan Province, China. BMC Infect Dis, 17(1), pp.573.

Flora, M.S., Amin, M.N., Karim, M.R., Afroz, S., Islam, S., Alam, A., & Hossain, M., 2013. Risk Factors of Multi-Drug-Resistant Tuberculosis in Bangladeshi Population: A Case Control Study. Bangladesh Medical Research Council Bulletin, 39(1), pp.34-41.

Harti, A.S., Murharyati, A., Sulisetyawati, S.D., & Oktariani, M., 2018. The Effectiveness of Snail Mucus (Achantina fulica) and Chitosan Towards Limfosit Proliferation in vitro. Asian Journal Pharmaceutical and Clinical Research, 11(3), pp.85-88.

Kobayashi, N., Hattori, T., Akter, S., Mizoue, T., & Ohta, K., 2017. Treatment Outcomes in Patients with Multidrug-Resistant Tuberculosis in Japan. European Respiratory Journal, 50(suppl 61).

Lan, Y., Li, Y., Chen, L., Zhang, J., & Zhang, H., 2019. Drug Resistance Profiles and Trends in Drug-resistant Tuberculosis at a Major Hospital in Guizhou Province of China Infect. Drug Resist, 12, pp.211–219.

Li, Q., Zhao, G., Wu, L., Lu, M., Liu, W., & Wu, Y., 2018. Prevalence and Patterns of Drug Resistance Among Pulmonary Tuberculosis Patients in Hangzhou, China. Antimicrob. Resist. Infect. Control, 7(61).

Li, Y., Cao, X., Li, S., Wang, H., Wei, J., & Liu, P., 2016. Characterization of Mycobacterium tuberculosis Isolates from Hebei, China: Genotypes and Drug Susceptibility Phenotypes. BMC Infect. Dis., 16(107).

Liu, Y., Zhang, X., Zhang, Y., Sun, Y., Yao, C., & Wang, W., 2018. Characterization of Mycobacterium tuberculosis Strains in Beijing, China: Drug Susceptibility Phenotypes and Beijing Genotype Family Transmission. BMC Infect. Dis, 18, pp.658.

Peng Lu, Qiao Liu, Leonardo Martinez, Haitao Yang, Wei Lu, Xiaoyan Ding, Lu, P., Liu, Q., Martinez, L., Yang, H., Lu, W., Ding, X., & Zhu, L., 2017. Time to Sputum Culture Conversion and Treatment Outcome of Patients with Multidrug-resistant Tuberculosis: A Prospective Cohort Study from Urban China. European Respiratory Journal, 49(3), pp.1-4.

McBryde, E. S., Meehan, M. T., Doan, T. N., Ragonnet, R., Marais, B. J., Guernier, V., & Trauer, J.M., 2017. The Risk of Global Epidemic Replacement with Drug-resistant Mycobacterium tuberculosis strains Int. J Infect Dis., 56, pp.14-20.

Migliori, G.B., Tiberi, S., Zumla, A., Petersen, E., Chakaya, J.M., Wejse, C., Torrico, M.M., Duarte, R., Alffenaar, J.W., Schaaf, H.S., Marais, B.J., Cirillo, D.M., Alagna, R., Rendon, A., Pontali, E., Piubello, A., Figueroa, J., Ferlazzo, G., García-Basteiro, A., Centis, R., Visca, D., D’Ambrosio, L., Sotgiu, G., 2020. MDR/XDR-TB Management of Patient and Contacs: Challenges Faacing the New Decade. The 2020 Clinical Update by the Global Tuberculosis Network. International Journal of Infectious Diseases, 92(S15-S25).

White, R.A., Lu, C., Rodriguez, C.A., Bayona, J., Becerra, M.C., Burgos, M., Centis, R., Cohen, T., Cox, H., D’Ambrosio, L., Danilovitz, M., Falzon, D., Gelmanova, I.Y., Gler, M.T., Grinsdale, J.A., Holtz, T.H., Keshavjee, S., Leimane, V., Menzies, D., Migliori, G.B., Milstein, M.B., Mishustin, S.P., Pagano, M., Quelapio, M.I., Shean, K., Shin, S.S., Tolman, A.W., Walt, M.L.v-d., Deun, A.V., & Viikleppet, P., 2016. Multidrug-resistant Tuberculosis Treatment Failure Detection Depends on Monitoring Interval and Microbiological Method. Eur Respir J, 48(4), pp.1160-1170.

Sarwani, D., Nurlaela, S., & Zahrotul, I., 2012. Faktor Risiko Multidrug Resistant Tuberculosis (MDR-TB). Jurnal Kesehatan Masyarakat, KEMAS, 8(1), pp.60-66

Sowajassatakul, A., Prammananan, T., Chaiprasert, A., & Phunpruch, S., 2014. Molecular Characterization of Amikacin, Kanamycin and Capreomycin Resistance in M/XDR-TB Strains Isolated in Thailand. BMC Microbiol., 14(165).

Sun, F., Li, Y., Chen, Y., Guan, W., Jiang, X., Wang, X., Ren, P., Li, J., Shi, J., He, G., Wu, M., Tang, P., Wang, F., Sheng, Y., Huang, F., Zhou, Z., Huang, H., Hong, L., Liu, Q., Zhang, Y., Zhang, W., 2019. Introducing Molecular Testing of Pyrazinamide Susceptibility Improves Multidrug-resistant Tuberculosis Treatment Outcomes: A Prospective Cohort Study. European Respiratory Journal, 53(3).

Tiberi, S., Walzl, N. d. P. G., Vjecha, M. J., Rao, M., Ntoumi, F., Mfinanga, S., Kapata, N., Mwaba, P., McHugh, T.D., Ippolito, G., Migliori, G.B., Maeurer, M.J., Zumla, A., 2018. Tuberculosis: Progress and Advances in Development of New Drugs, Treatment Regimens, and Host-directed Therapies. Lancet Infect Dis, 18, pp.e183–198.

Ullah, I., Javaid, A., Tahir, Z., Ullah, O., Shah, A., & Hasan, F., 2016. Pattern of Drug Resistance and Risk Factors Associated with Development of Drug Resistant Mycobacterium tuberculosis in Pakistan. PLoS ONE, 11(1 ), pp.e0147529.

Weldegebreal, S., & Mebrahtu, T., 2017. Anti-tuberculosis Drug Resistance in Ethiopia: Systematic Review. Int J Tuberc Lung Dis., 21(1), pp.18-22.

Wu, X., Yang, J., Tan, G., Liu, H., Liu, Y., Guo, Y., Gao, R., Wan, B., & Yu, F., 2019. Drug Resistance Characteristics of Mycobacterium tuberculosis Isolates From Patients With Tuberculosis to 12 Antituberculous Drugs in China. Frontiers in Cellular and Infection Microbiology, 9(345).

Refbacks

  • There are currently no refbacks.


Bookmark and Share


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.